Appleton Partners Inc. MA Sells 2,189 Shares of Zoetis Inc. $ZTS

Key Points

• Appleton Partners Inc. MA reduced its stake in Zoetis Inc. by 2.6%, selling 2,189 shares, leaving them with 80,909 shares valued at approximately $12.6 million.
• Zoetis recently reported earnings of $1.76 per share for the quarter, exceeding analysts’ expectations, with revenue of $2.46 billion, reflecting a 4.2% year-over-year growth.
• Five investment analysts have given Zoetis a Buy rating, while five have issued a Hold rating, resulting in a consensus rating of "Moderate Buy" with an average price target of $200.88.

Appleton Partners Inc. MA reduced its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 2.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 80,909 shares of the company's stock after selling 2,189 shares during the period. Appleton Partners Inc. MA's holdings in Zoetis were worth $12,618,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of ZTS. Nova Wealth Management Inc. bought a new stake in shares of Zoetis during the 1st quarter worth $25,000. 1248 Management LLC bought a new stake in shares of Zoetis during the 1st quarter worth $27,000. Saudi Central Bank bought a new stake in shares of Zoetis during the 1st quarter worth $29,000. Cornerstone Planning Group LLC boosted its holdings in shares of Zoetis by 79.3% during the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock worth $30,000 after buying an additional 88 shares during the period. Finally, ORG Partners LLC boosted its holdings in shares of Zoetis by 56.8% during the 2nd quarter. ORG Partners LLC now owns 232 shares of the company's stock worth $37,000 after buying an additional 84 shares during the period. 92.80% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ZTS shares. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Zoetis in a report on Saturday, September 27th. Leerink Partnrs downgraded shares of Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Argus reissued a "buy" rating and issued a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and reduced their price target for the company from $180.00 to $155.00 in a report on Thursday, July 17th. Finally, Piper Sandler increased their price target on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Monday, August 11th. Five investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $200.88.

Zoetis Price Performance

NYSE:ZTS opened at $146.45 on Monday. The company has a 50-day moving average of $149.79 and a 200-day moving average of $155.02. The company has a market capitalization of $64.91 billion, a price-to-earnings ratio of 25.21, a PEG ratio of 2.35 and a beta of 0.90. Zoetis Inc. has a 52 week low of $139.34 and a 52 week high of $196.55. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.04 and a current ratio of 1.76.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. The business had revenue of $2.46 billion during the quarter, compared to analysts' expectations of $2.41 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm's revenue for the quarter was up 4.2% on a year-over-year basis. During the same quarter last year, the company posted $1.56 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.